
Sarah Yim MD
Director, Office of Therapeutic Biologics & Biosimilars, FDA/CDER
Join to View Full Profile
10903 New Hampshire AveSilver Spring, MD 20903
Dr. Yim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Uniformed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 1992
Certifications & Licensure
- HI State Medical License 1993 - 2026
Publications & Presentations
PubMed
- 5 citationsPrescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary.Sophie Shubow, Qin Sun, Ai Len Nguyen Phan, Dana C Hammell, Maureen Kane
Clinical Pharmacology and Therapeutics. 2023-01-01 - 8 citationsImpact of Sex on Clinical Response in Rheumatoid Arthritis Patients Treated With Biologics at Approved Dosing Regimens.Lanyan Fang, Xuyang Song, Ping Ji, Yaning Wang, Janet Maynard
Journal of Clinical Pharmacology. 2020-12-03 - 4 citationsExposure-Response Modeling and Power Analysis of Components of ACR Response Criteria in Rheumatoid Arthritis (Part 1: Binary Model).Liang Li, Yi Zhang, Lian Ma, Ping Ji, Sarah Yim
Journal of Clinical Pharmacology. 2017-09-01
Press Mentions
- Interchangeable Biosimilars May Cut Costs or Cause ‘Cognitive Dissonance’April 17th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: